Navigation Links
UK company to demonstrate their commercially effective graphene production process
Date:4/6/2012

Haydale, a wholly owned subsidiary of British company Innovative Carbon Limited today announces that they will be exhibiting at Graphene 2012 from 10th April to 13th.

Graphene, a sheet of carbon just one atom thick, has been described as the new wonder material. First isolated at Manchester University in 2004, for which the team was awarded a Nobel Prize, the race has been on to produce it commercially. To support this work the UK Government recently announced a 50m investment into developing a research and technology hub to explore the commercialisation of Graphene. Similarly the EU has pledged 100m annually for the next 10 years looking at the exploitation of Graphene in Information and Communication Technology (ICT) and consumer applications.

The major players in this industry will be coming together at an international conference in Brussels next week. Haydale, based in South Wales and with close ties to leading UK Universities will be part of the British contingent. Their unique patented plasma based technology, which is winning plaudits around the world, enables the scaleable production of Graphene Nano Platelets (GNPs) from powdered graphite. The process can now produce commercial quantities of a consistently high quality in an economic and environmentally friendly way.

There are a vast array of applications for Graphene, but in Brussels Haydale will be displaying a range of current offerings produced via their novel patented process, including a transparent conductive membrane that could be a competitor of Indium Tin Oxide (one of the key components in photovoltaic cells and touch screen devices); graphene loaded polymer pellets; samples of GNPs and a conductive ink, capable of replacing some silver based products. The ink has many applications and could positively impact on the radio frequency identification and security industry. Haydale will have their scientists and engineers at the show to discuss these and other potential applications and to explain their split plasma process and the characterisation capability of the technology.

Haydale has now started to offer a range of GNPs and other materials to the open market under the brand HDPlas.

Critically, organisations can now use the HDPlas product range for product prototyping and analysis. Haydale offers expertise in running pilot trials to evaluate the effect their GNPs have on the client's materials and products and crucially assessing their suitability for large scale production. The key to take up is to know that commercial quantities are then available.

Haydale, who are moving to new purpose built state of the art facilities in South Wales, is now able to supply HDPlas from stock as well as to order. A technical analysis sheet, which includes typical characterisation data and representational images, has been prepared and will accompany the goods so that the buyer can instantly see the product specification without needing to spend valuable time and resource in independent verification procedures.

Commenting, Chairman Tony Belisario said:

"We are all very excited by the opportunity our patented process offers as a critical element of material replacement for enhanced performance of a vast array of potential applications. The market is looking for ways of using the new wonder material Graphene and we believe that we have the process that can now make the commercial quantities required by global companies. The cutting edge technology has been peer reviewed and we can now do "what it says on the tin". We have proved we can personalise solutions to a clients specific needs in a cost effective, environmentally friendly and innovative way. Graphene 2012 is a perfect place to launch our technology and we expect significant interest in Haydale."


'/>"/>

Contact: Trevor Phillips
trevor.phillips@hermesfinancialpr.co.uk
44-788-915-3628
Hermes Financial Public Relations
Source:Eurekalert

Related biology technology :

1. Regado Biosciences, Inc. to Present at Needham & Companys 11th Annual Healthcare Conference in New York, NY
2. Nycomed, a Takeda Company, Launches OmnarisĀ® Nasal Spray in the UAE for the Treatment of Allergic Rhinitis
3. Receptos to Present at the Cowen and Company 32nd Annual Health Care Conference
4. Incline Therapeutics to Present at the Cowen and Company 32nd Annual Health Care Conference
5. Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA
6. Aneesh Chopra to Serve as Senior Advisor to The Advisory Board Company
7. Meaningful Use Stage Two: The Advisory Board Company Helps Hospitals Set Strategy
8. Leading Pharmaceutical Marketing Research and Consulting Company Introduces Intelligent Efficiency Program
9. Oxford Finance Provides $15 Million Senior Secured Credit Facility to Private Equity Backed Healthcare Services Company
10. Fox Insurance Company Awarded $3.3 Million in Arbitration Against Former Pharmacy Benefit Manager
11. Monsanto Declared Worst Company of 2011 by NaturalSociety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016  Global demand for enzymes is forecast ... to $7.2 billion.  This market includes enzymes used ... biofuel production, animal feed, and other markets) and ... Food and beverages will remain the largest market ... of products containing enzymes in developing regions.  These ...
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... a mission to bring innovative medical technologies, services and solutions to the healthcare ... development and implementation of various distribution, manufacturing, sales and marketing strategies that are ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
Breaking Biology Technology:
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
Breaking Biology News(10 mins):